Over 2 Years Ago
1 Min Read
BEAM losing -7% today. A closer look at what's happening:
Beam Therapeutics Inc. (BEAM) is trading -7% lower at $58.78 today.
- The FDA placed its Investigational New Drug (IND) application for BEAM-201, a CAR-T candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic lymphoma (T-LL), on clinical hold.
Beam Therapeutics Inc. has been trading between a 52-week high of $116.91 and a 52-week low of $27.77. The stock has a market cap of $4.13 Billion.
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA.
Headlines
BEAM stock drops after FDA clinical hold on blood cancer candidate (NASDAQ:BEAM)
Seeking Alpha 08-01-22
Beam Therapeutics Says FDA Puts BEAM-201 IND Application On Clinical Hold
RTT News 08-01-22
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
GlobeNewswire 08-01-22
Will a Recession Cause a Housing Crash in 2022?
InvestorPlace 07-27-22
Take A Look At This Beam Therapeutics Inc. (NASDAQ: BEAM) Analysis Before You Invest
Stocks Register 07-20-22
Recommended Articles
